Compare Novavax Inc (NVAX) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Oscar Health Inc — how do they compare? Novavax Inc trades at $12.54 (market cap $1.82B), while Oscar Health Inc trades at $33.24 (market cap $10.22B). The key difference: Oscar Health Inc is far larger — about 5.6× Novavax Inc's market cap, and Novavax Inc is more actively traded (6,198,505 versus 4,123,394). Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Oscar Health Inc for 15 Days on average.
| NVAX | OSCR | |
|---|---|---|
Market Cap | $1.82B | $10.22B |
Volume | 6,198,505 | 4,123,394 |
Sector | Health | Health |
52-Week High | $12.56 | $33.81 |
52-Week Low | $6.22 | $10.85 |
Typical Hold Time | 59 Days | 15 Days |
Enterprise Value | $1.39B | $6.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
OSCR trades at $33.05, up 0.43% today, with strong technical momentum indicated by bullish moving averages. The company shows impressive growth with Q1 and Q2 2026 EPS beats and projected 2026 revenue of $15.3B. Valuation metrics appear reasonable with P/S of 0.63 and EV/EBITDA of 7.79, while profitability metrics show significant improvement from 2025 losses to projected 2026 net income of $551M.
The outlook remains positive with analyst consensus at $34.00 target and Strong Buy ratings from Zacks. Key opportunities include ACA market share gains and margin expansion, while risks center on rising medical costs and execution of growth targets. The stock faces near-term resistance at $34 with RSI suggesting potential overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
